During BIC22, Roche confirmed the solid (recovery) momentum in Core Pharmas, along with ample support from less severe biosimilar headwinds and COVID-19 business’s moderation, confidence with respect to Alzheimer’s drug and promising dynamics in Diagnostics. Although, near-term margins are likely to be restrained by R&D ambitions. Also, an inclination towards smaller acquisitions was reiterated. Overall, the Swiss giant remains on the right track to make-up for the (R&D and/or operational) disap ....
